Biosense Webster Showcases Cutting Edge Innovation and Leadership in AF
Ablation at HRS Annual Scientific Sessions 2013
Heart Rhythm 2013
DIAMOND BAR, Calif. -- May 8, 2013
Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of
cardiac arrhythmias, will showcase its portfolio of cutting edge innovative
technologies and its unrivaled leadership in atrial fibrillation ablation at
the 2013 Heart Rhythm Society’s 34^th Annual Scientific Sessions in Denver.
This meeting draws experts in cardiac rhythm management from around the globe
to explore the therapeutics and technologies shaping the future of this
The company will demonstrate its leadership at this meeting with a complete
portfolio of market-leading technologies and innovative solutions for
Electrophysiologists and Allied Health Professionals. The company’s full array
of support for physicians and their patients includes Clinical Support, Global
Education and Training Programs, Technical Service, Patient Education, and
other resources to support the expanded access to ablation treatment.
Speaking about the event, Shlomi Nachman, Worldwide President, Biosense
Webster, said, “We are excited to meet with our physician colleagues from
around the world and demonstrate our commitment to them and to their patients.
Biosense Webster stands alone in our singular focus on advancing EP ablation,
and our commitment to improving the lives of patients suffering from atrial
Among the highlights Biosense Webster will unveil for meeting attendees are:
*Introduction of the Biosense Webster Fluoroscopy Reduction Program
The Biosense Webster Fluoroscopy Reduction Program takes the advances of
the CARTO^® 3 System to the next level. It enables Electrophysiologists to
measure, track, evaluate and compare fluoroscopy time and provides
resources to become more completely informed about the opportunities to
reduce unnecessary radiation exposure during cardiac ablation procedures.
This industry-leading initiative incorporates continuous learning focused
on fluoroscopy reduction and specialized programs to involve lab staff,
while fostering knowledge sharing among physicians.
The Biosense Webster Fluoroscopy Reduction Program leverages innovative
techniques to optimize the use of existing tools such as the CARTO^® 3
System with its CARTOSOUND^® Module as well as new technologies including
CARTOUNIVU™ Module, CARTO^® System MEM version with the PENTARAY^® NAV
Catheter and THERMOCOOL^® SF Catheter with Curve Visualization.
*Results of the SMART-AF Trial: Ablation of Symptomatic Paroxysmal Atrial
Fibrillation Using Novel Contact Force Catheter
Andrea Natale, MD, Executive Medical Director of the Texas Cardiac
Arrhythmia Institute at St. David’s Medical Center and a member of the
SMART-AF study advisory committee, will present the 12-month safety and
effectiveness results from this IDE pivotal study which enrolled 172
subjects at 21 leading centers across the United States. The trial
investigated the use of the THERMOCOOL^® SMARTTOUCH^™ Catheter* with
contact force (CF) sensing technology for the ablation of symptomatic
paroxysmal atrial fibrillation.
Dr. Natale will present results during the Late Breaking Clinical Trials II
session on Friday May 10 at 2 p.m. in Four Seasons Ballroom 1 at the Colorado
Convention Center in Denver.
*Launch of the All-New Biosensewebster.com Website
The new www.Biosensewebster.com offers customers a new, richer online
experience to engage with Biosense Webster. Expanded to serve the needs of
the broad spectrum of Biosense Webster customers, the new site features
enhanced navigation and extensive product information including videos,
guides and other resources.
About AF and cardiac ablation
Atrial Fibrillation is the most prevalent arrhythmia, and is a leading cause
of stroke among people 65 years and older. Worldwide, it is estimated that 20
million people have AF, yet only ~130,000 are treated with ablation every
year. The public health implications of AF are a growing concern because those
with AF are at an increased risk of morbidity and mortality as well as a
reduced quality of life.
Most patients with AF today are treated with anti-arrhythmic drugs (AADs),
even though about half of them are refractory to these drugs. During cardiac
ablation, energy is delivered through the catheter to those areas of the heart
muscle causing the abnormal heart rhythm. This energy “disconnects” the
pathway of the abnormal rhythm. Cardiac ablation is commonly used for “simple”
arrhythmias, like Wolff-Parkison-White Syndrome and atrioventricular nodal
re-entry tachycardia (AVNRT), and is increasingly being used for more complex
arrhythmias like ventricular tachycardia and atrial fibrillation. THERMOCOOL^®
Navigation Catheters are approved for drug refractory recurrent symptomatic
paroxysmal atrial fibrillation, when used with CARTO^® Systems (excluding
NAVISTAR^® RMT THERMOCOOL^® Catheter).
About Biosense Webster, Inc.
Biosense Webster, Inc., part of the Johnson & Johnson Family of Companies,
pioneered EP diagnostic catheters more than 20 years ago and continues to lead
the industry as an innovative provider of advanced cardiac diagnostic,
therapeutic, and mapping tools. As the leader in EP navigation systems and
ablation therapy, Biosense Webster, Inc. has technology that includes the
largest installed base of cardiac mapping navigation systems worldwide in
leading hospitals and teaching institutions. For more information about
Biosense Webster and its products, please visit: www.biosensewebster.com (this
site is intended for US visitors only).
* The THERMOCOOL^® SMARTTOUCH™ Catheter is approved for investigational use
only and is not for sale in the United States.
Dr. Natale is compensated for his services as a member of the company’s
scientific advisory board and provides other consulting services.
Biosense Webster, Inc.
Sandy Pound, 732-524-1941
Press spacebar to pause and continue. Press esc to stop.